Search Within

Anas Younes

Formats
  1. Meeting Abstract (153)
  2. Journal Article (136)
  3. Book Section (13)
  4. Book Whole (4)
  5. Editorial (4)
  6. Review (4)
  7. Conference Paper (2)
  8. Research Letter (2)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (320)
  2. Department of Medicine (320)
  3. Executive Committee, Center for Hematologic Malignancies (320)
  4. Hematologic Malignancies, Division of (320)
  5. Lymphoma (320)
  6. Hematology-Oncology Fellows (98)

More Groups

People
  1. Andrew Zelenetz (89)
  2. Connie Batlevi (81)
  3. David Straus (74)
  4. Matthew Matasar (68)
  5. Anita Kumar (67)
  6. Paul Hamlin (67)

More People

Years
  1. 2024 (3)
  2. 2023 (7)
  3. 2022 (11)
  4. 2021 (13)
  5. 2020 (26)
  6. 2019 (53)

More Years

Publications
  1. Blood (91)
  2. Journal of Clinical Oncology (25)
  3. Hematological Oncology (22)
  4. Haematologica (16)
  5. British Journal of Haematology (13)
  6. Cancer Research (10)

More Publications

Publishers
  1. American Society of Hematology (99)
  2. American Society of Clinical Oncology (27)
  3. Wiley Blackwell (25)
  4. Nature Publishing Group (19)
  5. Springer (17)
  6. American Association for Cancer Research (16)

More Publishers

Results (320)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 dose-finding study investigating CA-4948, an IRAK4 kinase inhibitor, in patients with R/R NHL: Report of initial efficacy and updated safety information
    Meeting Abstract

    Younes, A.; Nowakowski, G.; Rosenthal, A. C.; Leslie, L. A.; Tun, H. W.; Lunning, M. A.; Isufi, I.; Martell, R.; Patel, K.
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and efficacy of atezolizumab in combination with rituximab plus CHOP in previously untreated patients with diffuse large B-cell lymphoma (DLBCL): Updated analysis of a phase I/II study
    Meeting Abstract

    Younes, A.; Burke, J. M.; Cheson, B. D.; Diefenbach, C.; Ferrari, S.; Hahn, U. H.; Hawkes, E. A.; Khan, C.; Lossos, I. S.; Musuraca, G.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A multi-center dose-finding study to assess safety, tolerability, pharmacokinetics and preliminary efficacy of fimepinostat (CUDC-907) in combination with venetoclax in patients with relapsed/refractory (R/R) lymphoma
    Meeting Abstract

    Younes, A.; Batlevi, C. L.; Cohen, J. B.; de Vos, S.; Landsburg, D. J.; Myint, Z. W.; Patel, K.; Phillips, T. J.; Smith, S. M.; Westin, J. R.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Inhibition of PIM kinases targets synthetic vulnerabilities and enhances antigen presentation in B-cell lymphoma
    Meeting Abstract

    Mondello, P.; Tarantelli, C.; Cascione, L.; Arribas, A.; Rinaldi, A.; Younes, A.; Bertoni, F.
    Blood (2019)

    Fulltext@MSK | Save
  • Expectant management of extranodal marginal zone lymphoma of bronchial-associated lymphoid tissue (BALT)
    Meeting Abstract

    Leyfman, Y.; Joffe, E.; Drill, E.; Rajeeve, S.; Zelenetz, A. D.; Palomba, M. L. L.; Moskowitz, C. H.; Portlock, C. S.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for Stage 3/4 classical Hodgkin lymphoma (cHL): 4-year update of the ECHELON-1 study
    Meeting Abstract

    Bartlett, N. L.; Straus, D. J.; Dlugosz-Danecka, M.; Alekseev, S.; Illes, A.; Lech-Maranda, E.; Feldman, T. A.; Smolewski, P.; Savage, K. J.; Walewski, J.; more...
    Blood (2019)

    Fulltext@MSK | Save